9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial

R.Jotte; P.R.Conkling; C.Reynolds; C.Shah; M.Galsky; L.Klein; J.F.Fitzgibbons; R.McNally; J.W.Oliver; M.Renschler

首页> 外文期刊>European Journal of Cancer Supplements >9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial

【24h】

9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial

机译：9120对柔和的一线铂类化疗敏感的广泛疾病小细胞肺癌（ED-SCLC）中的二线氨柔比星vs拓扑替康：随机2期试验的更新结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共2页
作者
R.Jotte; P.R.Conkling; C.Reynolds; C.Shah; M.Galsky; L.Klein; J.F.Fitzgibbons; R.McNally; J.W.Oliver; M.Renschler;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. [J] . Jotte R, Conkling P, Reynolds C, Journal of Clinical Oncology . 2011,第3期

机译：单药氨柔比星或拓扑替康作为对一线铂类化学疗法敏感的小细胞肺癌患者的二线治疗的随机II期试验。
2. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. [J] . Jotte R, Conkling P, Reynolds C, Journal of Clinical Oncology . 2011,第3期

机译：单孕糖尿病或Topotecan的随机期II试验作为对小细胞肺癌对一线铂化疗敏感的患者的二线治疗。
3. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. [J] . Jotte R, Conkling P, Reynolds C, Journal of Clinical Oncology . 2011,第3期

机译：单孕糖尿病或Topotecan的随机期II试验作为对小细胞肺癌对一线铂化疗敏感的患者的二线治疗。
4. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
5. Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer [O] . Hao Chen, Nobuyuki Horita, Kentaro Ito, 2020

机译：无进展生存的危害比是III期随机对照试验中总存活的优异预测因子评估了一线化疗进行广泛疾病的小细胞肺癌
6. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401 [O] . Nogami, Naoyuki, Hotta, Katsuyuki, Kuyama, Shoichi, 2011

机译：氨柔比星和拓扑替康联合疗法在复发或广泛疾病小细胞肺癌患者中的II期研究：冈山肺癌研究小组试验0401

9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial

著录项

相似文献

相关主题

期刊订阅